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Background: Atopic dermatitis (AD) is the most common canine allergic skin disease and can significantly affect
the quality of life of affected dogs. Treating canine AD with ciclosporin has been a subject of great interest in
recent years. Many studies have provided substantial evidence of ciclosporin efficacy and safety in canine AD
management, and for several years ciclosporin has been recognised as a major component of canine AD
multimodal therapy. As a chronic condition, canine AD requires life-long medical management and treatment
success relies in large part on product ease of administration. Two studies were conducted to assess the
comparative voluntary acceptance and consumption of Cyclavance® (Virbac), a new oral liquid formulation of
ciclosporin, and Atopica® (Novartis) either added to a small quantity of kibbles (study 1) or administered directly
into the dog’s mouth (study 2).
Results: Over the course of the two studies 70 dogs assessed each of the ciclosporin formulations and 320
individual tests were performed for each tested product. Immediate prehension (in less than 2 seconds) occurred
significantly more often with Cyclavance® (90.6% of the tests) than with Atopica® (14.4% of the tests) when
products were mixed with 30 grams of dry food (p < 0.001). Moreover, Cyclavance® was significantly more often
easily accepted than Atopica® (99.3% vs 27.1% of the tests, respectively) when products were administered directly
into the dogs’ mouth (p < 0.0001). Cyclavance® was also more often totally consumed (98.3% of the tests) than
Atopica® (2.2% of the tests) when mixed with a small amount of food (p < 0.001). However, both products were
totally consumed once administered directly into the dogs’ mouth.
Conclusions: By facilitating cicloporin administration and consumption, Cyclavance® liquid formulation offers an
interesting alternative to capsules that may improve dosing compliance and therefore the ability to benefit from
the therapeutic effects in the long-term treatment of canine AD.
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Ciclosporin is a lipophilic cyclic polypeptide with power-
ful immunosuppressive and immunomodulatory proper-
ties which was first licensed for the management of
canine atopic dermatitis (AD) in 2002 as Atopica® (Novartis
Animal Health) and is now approved and available in over
20 countries worldwide.
Ciclosporin at an initial dosage of 5 mg/kg, PO, every
24 hours has been largely demonstrated to be highly* Correspondence: christelle.navarro@virbac.com
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unless otherwise stated.effective in the treatment of AD in dogs and remains now-
adays one of the most important tools within a multi-
modal treatment strategy [1]. As a consequence, the
International Task Force for Canine Atopic Dermatitis
(now the International Committee for Allergic Diseases in
Animals [ICADA]) practice guidelines for the treatment of
canine AD has specifically been recommending the use of
ciclosporin as one of the management tool for chronic AD
since 2010. However, the non-palatable capsule formula-
tion of Atopica raises some concerns about compliance in
a long-term treatment strategy.
A new oral liquid formulation of ciclosporin (Cyclavance®,
Virbac) has recently been approved in Europe, thus offeringl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sible to adjust individual dosages with accuracy. It is a
100 mg/ml oral solution indicated in dogs for the treatment
of chronic clinical manifestations of AD. After oral admin-
istration of ciclosporin at the labeled recommended dose
rate of 5 mg/kg bodyweight, peak blood concentrations are
achieved within 1–2 h [2]. Being lipophilic, ciclosporin is
distributed widely in the body with skin and adipose tissue
acting as principal storage sites. The concentration of
ciclosprin in skin is up to 10 times higher than that in
blood. The high skin concentrations and the relatively long
half-life of the drug (average 8.6 h) support once daily dos-
ing in dogs [2,3]. Therefore, Cyclavance®, like Atopica®,
could initially be given daily until a satisfactory clinical im-
provement is seen and then can be given every other day,
and eventually in some cases every 3 to 4 days, as a main-
tenance dose [4].
The liquid form of ciclosporin has been designed to be
easier to administer than the capsule form. Our hypoth-
esis was therefore that it would be more acceptable to
dogs and reduce the need for forced administration. It
was decided to compare, in two separate studies, the
dogs’ voluntary acceptance and consumption of both
presentations when presented in a bowl mixed with a
small amount of food (study 1), and when administered
directly into the mouth (study 2).
Methods
Tested products
The products tested were Cyclavance® 100 mg/ml oral so-
lution (Virbac, France) and Atopica® 50 mg or Atopica®
100 mg capsules (Novartis Animal Health, Switzerland).
The products were administered orally.
Ethics statement
The studies were carried out in accordance with the
relevant European legislation and Virbac’s chart of Ethics
(Study 1: EU-2014/11-13; Study 2: CE VB-2012-25-001).
Study 1
Animals
Sixty adult healthy dogs, 32 females and 28 males, were in-
cluded. The breeds represented included various unspeci-
fied mixed breeds (58%), Beagle (20%), Fox Terrier (8%),
Spaniel (5%), Cocker Spaniel (3%), Jack Russel Terrier,
Shetland Sheepdog, and Schnauzer (less than 2% each).
The dogs were aged between 1.5 and 16.2 years with a
mean age of 7.3 (±3.3) years and weighed between 7.7 and
23.8 kg with a mean weight of 13.6 (±4.0) kg. Animals
were housed, managed and fed as normal and no alter-
ation was required for the purpose of the study. Water
was given ad libitum. The dogs were fed once per day
with a complete dry maintenance food for adult dogs at
8 am each day.Study design
This mono-center, controlled, randomised cross-over
study was conducted in accordance with the rules of the
European Union on Animal welfare in a specialised
kennel. Given the obvious difference between the formu-
lations (oral solution vs capsule) of the two tested prod-
ucts, the palatability tests could not be blinded. At
enrolment the animals were divided into three groups
consisting of twenty dogs each according to their body-
weight (≤10 kg, 10–14.9 kg, ≥15 kg). Dogs were then
randomly allocated within each group to Sequence A or
Sequence B in a tiered fashion based on their sex and age.
The testing consisted of two sequences of three days of
product administration separated by two days of wash-
out. Sequence A consisted of Atopica® for three days,
followed by two days of wash-out, then Cyclavance® for
three days. Sequence B consisted of Cyclavance® for three
days, followed by two days of wash-out, then Atopica® for
three days.Product testing
The prehension and consumption of Cyclavance® was
compared with that of Atopica® by the means of accept-
ance tests. These started at 2 pm on each study day. The
dogs received 0.05 ml/kg of Cyclavance® or one capsule
of Atopica® mixed with 30 grams of dry food presented
in a bowl (Cyclavance® was poured onto the kibbles and
the whole capsule of Atopica® was buried in kibbles). Ac-
cording to label recommendation, the dogs weighing be-
tween 7.5 and 15 kg were administered Atopica® 50 mg
and the dogs weighing between 15 and 29 kg were pre-
sented with Atopica® 100 mg. The bowl containing the
food and product was positioned on the floor inside the
animal’s pen. A timer was started when the dog was
allowed access to the bowl and was stopped when the
product entered the animal’s mouth. The time to take
the product was recorded as less than 2 seconds or more
than 2 seconds. If after 60 seconds, the product had not
been taken into the mouth, the test was terminated and
the prehension was assessed as “no intake”. Each time
kibbles or the capsule were prehended, the dog was ob-
served during a further 5 minutes in order to register if
it swallowed the product or if it spat it out. The amount
of liquid and food remaining in the bowl were also
recorded.Classification of product prehension and consumption
Prehension was defined as the animal voluntarily taking
the product into the mouth. The prehension of the
tested products was further classified as immediate (less
than 2 seconds), delayed (more than 2 seconds), or no
prehension. Product and kibble consumption was classi-
fied as total (100%), partial, and none (0%).
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The dogs were monitored closely throughout the study
with a requirement for any abnormal events to be re-
corded in the individual clinical report form of each dog.
Experiment 2
Animals
Twenty adult healthy Beagle dogs, 12 females and 8
males, were enrolled. The dogs were aged between 0.5
and 3.2 years with a mean age of 2.2 (±0.8) years and
weighed between 9.6 and 14.2 kg with a mean weight of
11.6 (±1.5) kg. Water was given ad libitum. The dogs
were fed once per day with a complete dry maintenance
food for adult dogs and housed in individual pens.
Study design and test procedure
For this mono-center, controlled, randomised study the
animals were randomly allocated to receive Cyclavance®
or Atopica® in a tiered fashion according to their body-
weight and sex. The products were administered once
per day during the 14-day study period at least 2 hours
before meal time. In the Cyclavance® group the dosage
was progressively increased from 1 to 4 mg/kg over a
four-day period (from D0 to D3) then 5 mg/kg were ad-
ministered daily over the ten remaining days (from D4
to D13). In the Atopica® group one capsule of Atopica®
50 mg was administered daily to all dogs as per the label
recommendations. As a result, the dosage of ciclosporin
given in this group varied between 3.5 and 5.2 mg/kg
depending on bodyweight.
Classification of product voluntary acceptance and
consumption
Cyclavance® was administered directly in the dog’s mouth
with the syringe. Atopica® capsules were offered by the
hand and if not taken within 1 minute were inserted into
the mouth.
The product intake was classified as voluntary accept-
ance (Syringe easily inserted into the mouth or capsule
taken from the hand of the technician, combined with
willingness to swallow the product) or forced adminis-
tration (need for a strong animal handling to insert the
syringe into the dog’s mouth or need to insert the cap-
sule at the back of the throat or need for restraint to en-
sure swallowing).
Tolerance assessment
A clinical examination of each dog including stool ap-
pearance, appetite and overall condition was performed
before the beginning of the test procedure (on D0) and
on each study day. Photographs of the faecal matter
were taken each morning. Fecal scores were then blindly
assessed at study completion by two different operators
for each dog on each study day using a previously-validated scoring chart (scores 0–5) [5]. Furthermore, all
dogs were weighed on D0, D7 and D14 and fasting blood
samples were taken on D0 and D14 for haematology and
biochemistry analysis. The number of dogs showing at
least one gastrointestinal event (vomiting and/or diar-
rhoea) occurring over the first 4 study days and during
the course of the entire study was compared between
product groups.
Statistical analyses
Statistical analyses were performed using SAS 9.3. In
study 1, product prehension, product consumption and
food consumption were compared between products
using a general linear model (Proc GLM in SAS) for
crossover study, with sequence, dog (sequence), product,
period and product*period as fixed effects. This model
was used to show if there was a relation or not between
the product prehension, the product consumption, the
food consumption, and the product, taking into account
the period and the sequence.
In study 2, product acceptance was compared between
products using a generalized linear model for repeated
measures (Proc GENMOD in SAS), with group and day
as fixed effects. This model was used to show if there
was a relation or not between the product acceptance
and the product, taking into account the repeatability of
the measures (once per day, during 14 days).
The significance threshold was set at 5% for both studies.
Results
Study 1
Over the course of the study, a total of 180 individual
voluntary acceptance tests were completed for each
tested product. Figure 1 demonstrates the prehension by
category for each product. Immediate prehension rates
(product voluntarily taken into the dog’s mouth in less
than 2 seconds) were significantly higher for Cyclavance®
(163 of 180 tests; 90.6%) compared to Atopica® (26 of
180 tests; 14.4%) (p < 0.001). Table 1 shows the breakdown
of prehension rates for each tested product by bodyweight
range. The results remain in line with those observed with
all dogs independently of their bodyweight. When consid-
ering product consumption, a statistically significant dif-
ference (p < 0.001) between products was also shown in
favour of Cyclavance® with total consumption in 177 tests
(98.3%) versus 4 tests (2.2%) for Atopica®. Figure 2 pro-
vides the details of the consumption rates by category. In
one test (0.6%), a dog consumed partially the dose of
Cyclavance®, but in all other tests, the dogs ingested the
total amount of liquid with the kibbles. Some dogs took
the capsule of Atopica® into their mouth and then spat it
out immediately, but the great majority of the dogs did
not take the capsule. The dogs’ bodyweight ranges had no
impact on consumption for either product as shown in
Figure 1 Product prehension in study 1. This chart presents the level of spontaneous prehension for the tested products. * Statistical difference
between the products (p < 0.05). Immediate prehension rates were significantly higher for Cyclavance® compared to Atopica® (p < 0.001).
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products. No adverse event was reported during the
course of the study for either tested product.Study 2
Over the study period, a total of 140 tests were per-
formed for each tested product. Cyclavance® was signifi-
cantly more often easily accepted than Atopica® (99.3%
vs 27.1% respectively; p < 0.0001) as shown in Figure 3.
When focusing on the study period between D4 and
D13 where all dogs received approximately 5 mg/kg
ciclosporin daily, a similar difference between groups
was noted (99.0% vs 31.0% respectively; p < 0.0001). Stat-
istical analysis further confirmed that the same observa-
tion remained valid throughout the study period without
any influence of study days as shown in Figure 4. In
most tests, Atopica® had to be forcibly administered
whereas Cyclavance® was easily accepted by the dogs in
100% of the tests on all study days except on D13 forTable 1 Breakdown of product prehension rates per
dogs’ bodyweight range in study 1








Less than 10 kg Cyclavance® 54 (90%) 6 (10%) 0 (0%)
Atopica® 15 (25%) 6 (10%) 39 (65%)
10 to 15 kg Cyclavance® 60 (100%) 0 (0%) 0 (0%)
Atopica® 7 (11.7%) 6 (10%) 47 (78.3%)
More than 15 kg Cyclavance® 49 (81.7%) 9 (15%) 2 (3.3%)
Atopica® 4 (6.7%) 5 (8.3%) 51 (85%)one dog. One animal given Atopica® from D0 to D13
was able to spit out the capsule even when it was
inserted into the back of the throat. Nevertheless, with
forced administration it was always possible to ensure
that the product was totally consumed except on 2 occa-
sions where a dog bit the soft Atopica® capsule and the
contents were partially spilt on the floor. No significant
changes were noted in the dogs’ bodyweight. Rectal tem-
peratures remained within normal values for all dogs.
The overall condition was good for all dogs throughout
the study period. No dog showed dehydration or a change
of appetite. Fecal scores were very similar between both
products. However, some dogs showed transitory diarrhoea
and/or vomiting throughout the study period. During the
14-day study duration, there was no difference in the num-
ber of animals showing at least one gastro-intestinal event
(6 in the Atopica group vs 7 in the Cyclavance group).
However, over the first 4 days of the study, during which
the Cyclavance group was receiving a progressively increas-
ing dose, there were half as many dogs showing at least
one gastrointestinal event in the Cyclavance group versus
the Atopica group (respectively 3 vs 6). Haematological
and biochemical parameters remained within normal
ranges between D0 and D14 in all dogs.Discussion
Canine AD is a chronic disease that requires long-term
treatment strategy. Thus, ease of administration, volun-
tary acceptance and consumption of drugs used for AD
management are of primary importance to promote
treatment success. To the authors’ knowledge, despite a
high number of publications and studies performed on
dogs, up to now no study had been specifically designed
Figure 2 Product consumption in study 1. This chart presents the level of consumption for the tested products. * Statistical difference
between the products (p < 0.05). Total consumption was significantly higher for Cyclavance® than Atopica® (p < 0.001).
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ciclosporin. The procedures used in the reported studies
(appropriate investigator and animal training to test pro-
cedures, tests performed at a fixed time every day, use of
a cross-over design and of a randomised allocation plan)
are derived from those used in the pet food industry in
order to reduce bias [6,7]. Furthermore, 20 dogs and at
least two days were reported in previous publications to
be sufficient when determining palatability differences
between any two food samples with sufficient accuracy
and efficiency [8]. In the present studies, acceptance
tests were run over a period of as long as 14 days. How-
ever, some limitations of the reported studies can be
pointed out. As for most palatability studies, study 2 was
performed with only one dog breed (Beagles) and even if
no breed recommendations have been made for assessingTable 2 Breakdown of product consumption per dogs’
bodyweight range in study 1
Dogs’ weight Product Consumption
Total Partial None
Less than 10 kg Cyclavance® 60 (100%) 0 (0%) 0 (0%)
Atopica® 2 (3.3%) 0 (0%) 58 (96.7%)
10 to 15 kg Cyclavance® 60 (100%) 0 (0%) 0 (0%)
Atopica® 2 (3.3%) 0 (0%) 58 (96.7%)
More than 15 kg Cyclavance® 57 (95%) 1 (1.7%) 2 (3.3%)
Atopica® 0 (0%) 0 (0%) 60 (100%)both food and drug palatability, the sample used was not
representative of the real population of dogs. The environ-
mental conditions were not strictly controlled throughout
study 1 and it is not possible to discount the possibility
that variations may have affected the result between test-
ing periods. Finally, it has been suggested that acceptance
of a product may differ between animals kept under ex-
perimental and field conditions and that definitive assess-
ment of palatability should be done in the consumers'
home [9]. However, the results of the two studies reported
in this paper certainly give clear indications on how Cycla-
vance® will be accepted by owners’ dogs. Indeed, since the
assessment of its full consumption can be considered as a
direct measure of its compliance [9], Cyclavance®, either
administered with a small amount of food or directly into
the dogs’ mouth, should help facilitate long-term adminis-
tration. In that sense, it is interesting to note that, in study
1, 59 dogs out of 60 had a complete consumption of the 3
doses of Cyclavance® over the 3-day study period (indeed
only 1 dog had partial consumption on day 1 and then no
consumption on days 2 and 3) whereas no dogs in the
Atopica group took the 3 doses (2 dogs took 2 doses). Fur-
thermore, besides the ease of use of an oral syringe, Cycla-
vance® also enables more accurate dosage.
In an attempt to further facilitate product administra-
tion, ciclosporin was administered with a small amount
of food in study 1. Knowing that the average food con-
sumption per dog and per day was comprised between
200 and 400 grams during the course of this study, the
AFigure 3 Overall product voluntary acceptance in study 2. This chart presents the voluntary acceptance of the tested products (all tests
combined). * Statistical difference between the products (p < 0.05). Cyclavance® was significantly more often spontaneously prehended than
Atopica® (p < 0.0001).
Figure 4 Evolution of product voluntary acceptance throughout the study 2 period. This chart presents the voluntary acceptance of the
tested products on each study day. * Statistical difference between the products (p < 0.05). Cyclavance® was significantly more often easily
accepted than Atopica® throughout the study period without any influence of study days (p < 0.0001).
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about 10% of the dogs’ daily food intake. Moreover, con-
sidering that the acceptance tests took place each day
5.5 hours after the dogs’ meal time, it can be assumed
that in study 1, the study design is compatible with the
recommendation that the products should be given apart
from meals. The effect of feeding on ciclosporin oral
bioavailibity and efficacy is controversial in the literature.
The absolute oral bioavailability of ciclosporin in dogs is
low and highly variable. This can be explained by the
high molecular weight of the drug, its low water solubil-
ity, the effect of the P-glycoprotein efflux pump at the
intestinal level, and metabolism by cytochrome P450 3A
enzymes located in the small intestinal mucosa and liver
[2]. The product labelling for Atopica® and Cyclavance®
therefore mention that both products should be admin-
istered at least 2 hours apart from feeding rather than at
mealtimes. This precaution of use is supported by one
study that tested the influence of the feeding status at
the time of administration. The administration of ciclos-
porin to healthy beagles with their daily meal decreased
the bioavailability and increased the individual variability
of drug absorption [10]. In the same study, pharmacoki-
netic parameters in fed or fasted dogs receiving ciclos-
porin as solution or capsule were measured. Cmax
tended to be lower after capsule administration and was
also decreased by 23% in fed dogs compared with fasted
dogs. In five of the 16 dogs which received the drug with
food, Cmax and AUC did not reach 50% of the mean
values obtained in the fasted dogs [10]. However, clinical
response to therapy is a more reliable method of asses-
sing efficacy of ciclosporin than interpretation of ciclos-
porin blood level. Moroever no correlation was found
between clinical improvement and ciclosporin blood
concentrations [11]. Indeed, in AD, ciclosporin target
cells include Langerhans cells, mast cells, eosinophils
and keratinocytes located in the skin. Since the drug
concentration in epidermis and dermis is about 10-fold
higher than in the blood, drug concentration in the skin
may be sufficient to inhibit the activation of these cells
involved in the inflammatory process [10]. Furthermore,
another study found that administration of ciclosporin
with food to dogs treated for AD did not influence the
clinical response [12] and clinical experience has shown
that efficacy seems unaffected by administration with
food [3]. In conclusion, mixing ciclosporin with a small
amount of food (i.e. 30 grams as in study 1) for easier
administration should have, if any, very limited effects
on its bioavailability or, more importantly, on the clinical
response when used in canine AD.
Results of previous studies have suggested that ciclos-
porin is safe in dogs. Most adverse effects are manage-
able and/or without clinical significance, even over many
years of treatment [1]. The most common adverseeffects are gastrointestinal tract abnormalities during the
first weeks of treatment [13,14]. In a meta-analysis of
672 atopic dogs treated with ciclosporin, gastrointestinal
problems were recorded in 45 percent of dogs [15].
Vomiting was reported in 25 to 31 % of dogs and soft
stools, diarrhea and/or other problems affected 18 to 20
% of the dogs receiving ciclosporin [15]. Most of the
gastrointestinal upsets appear to be mild, require med-
ical intervention only in rare instances [14], rarely re-
quire discontinuation of ciclosporin [14], and generally
improve spontaneously upon further administration [16].
When drug related, most of these reactions appear to be
dose dependent, and they resolve with dose reduction or
treatment discontinuation [5]. Suggestions from the lit-
erature to reduce the incidence of vomiting and/or diar-
rhoea are to administer ciclosporin with a small amount
of food [11] and/or to start treatment with a low dose (1
to 2 mg/kg every 24 hours) gradually increasing to the
therapeutic dose (5 mg/kg every 24 hours) [15]. In study
2 we took advantage of the flexibility permitted by the
use of the oral dosing syringe with a liquid formulation
and applied this strategy for Cyclavance®. However the
number of dogs in this study was not sufficient to an-
swer the question of whether there will be any statisti-
cally significant difference between dogs receiving a
progressive dosage increase of ciclosporin from 1 to
5 mg/kg over the first five days of dosing compared to
those administered 5 mg/kg bodyweight from the onset
of treatment. This subject should be further explored in
future studies in field conditions using atopic dogs.
Such a progressive onset of treatment is unlikely to
have any real impact on treatment efficacy. Usually, even
if owners report a significant reduction of pruritus as
early as 7–8 days in dogs treated with ciclosporin alone,
it requires approximately three to four weeks of therapy
at 5 mg/kg once daily for maximal clinical improvement
[3,16]. The extent and severity of skin lesions is im-
proved by approximately 50% in the first 4 weeks of
treatment with a further improvement of up to 60–80%
of the lesions severity obtained in the maintenance
phase. The extent of improvement seems to be however
more dependent upon treatment duration than the daily
dose related to the body weight [10]. Furthermore, in a
study where the initial dosage of ciclosporin ranged from
3.3 to 6.6 mg/kg, PO, every 24 hours, it was found that
in this dosage range, there was no relationship between
dosage and clinical response after 4 weeks [10]. This
suggests that in this study, clinical response plateaued at
dosages higher than 3.3 mg/kg. On the other hand, in a
previous study a dosage of 2.5 mg/kg, PO, every 24 hours
for 6 weeks was found to be significantly less effective
than a dosage of 5 mg/kg [14]. These data suggest the
need to conduct studies to evaluate ciclosporin efficacy
in the treatment of canine AD after progressive dosage
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the impact on the frequency of side effects observed
during this period.
Conclusion
The liquid formulation of Cyclavance® is easy to admin-
ister and enables accurate dosage adjustments. Further-
more, the results of two distinct studies showed that the
voluntary prehension, acceptance and consumption of
Cyclavance® is significantly better than that of Atopica®
when administered either directly into the dog’s mouth
or mixed with a small amount of food. In chronic diseases
such as canine AD requiring a long-term treatment
strategy, these attributes are of primary importance for
good patient and owner dosing compliance and thereby
therapeutic success.
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